Clinical Study of Coronary Extension Catheter

• Coronary Extension Catheter (Device): For the subjects who met the requirements of the study protocol, the BM coronary extension catheter was used for treatment.

Primary outcomes

• Device Delivery Success Rate [Immediately after procedure, 0 day]: Device delivery success is defined as the successful delivery of the target device (balloon and/or stent) to the target lesion after the use of the study device during percutaneous coronary intervention (PCI).

Secondary outcomes

• Procedural Success Rate [Immediately after procedure, 0 day]: Procedural success is defined as residual stenosis of the target lesion ≤30% (by visual estimation) and TIMI flow grade 3 after PCI.
• Device Usage Evaluation [Immediately after procedure, 0 day]: The device usage evaluation includes: pushability, support, overall ease of use, device trackability, and radiopacity. There are four grades, ranging from poor to excellent.
• Adverse events and serious adverse events related to the study device [Endpoints will be measured through hospital discharge (expected to be within 7 days)]: Adverse events and serious adverse events related to the study device during the study.
• Adverse Event and Serious Adverse Event [Endpoints will be measured through hospital discharge (expected to be within 7 days)]: Occurrence of adverse events and serious adverse events during the study.
• Device defects [Immediately after procedure, 0 day]: Incidence of device defects.

Sex: All, ages: 18 Years to any

Inclusion Criteria:

* Age ≥18 years, regardless of gender;
* Patients suitable for percutaneous coronary intervention (PCI) and for whom the use of an extension catheter is planned to assist the intervention;
* Ability to understand the purpose of the study, willingness to voluntarily participate, and ability to provide written informed consent.

Exclusion Criteria:

* Reference vessel diameter < 2 mm;
* Presence of thrombus in the target vessel;
* Unprotected left main coronary artery disease;
* Acute myocardial infarction occurring within 7 days prior to enrollment;
* Known intolerance to anticoagulant or antiplatelet therapy, or known allergy to contrast media;
* Concurrent severe hepatic or renal disease, or other severe systemic conditions that render the patient unsuitable for PCI;
* Pregnant or lactating women;
* Currently participating in another clinical trial of a drug or medical device without having reached the primary endpoint or completed the trial;
* Any other condition that, in the investigator's opinion, makes the patient ineligible for participation in this study.